Cosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and CanadaBuilding on Its Recent Acquisition of the CCX0722 Intellectual Property, Cosmos Health Owns the Technology Outright and Is Now Pursuing Patent Protection Across Four Major Healthcare Markets Within the $190+ Billion Global Weight Management Category Advances international patent application WO2025108566A1, titled "Hydrogel for Body Weight Management," into the U.S., Europe, Australia, and Canada — four of the world's largest healthcare markets Builds on Cana Laboratories' acquisition of the patent application from Cloudpharm, bringing full ownership of the underlying intellectual property into the Cosmos Health portfolio, with no licensing fees, royalty-sharing, or third-party IP dependency Three-plus years of disciplined R&D execution — from concept in 2022 through pilot production, scale-up, and final-stage development Positioned within the rapidly growing global weight management market, estimated at $190.6 billion in 2025 and projected to reach $562.2 billion by 2033 at a 14.2% CAGR, as obesity becomes one of healthcare's most capital-intensive categories Management believes CCX0722 represents one of Cosmos Health's most strategically significant proprietary assets, with multiple potential paths to value creation — including licensing, co-development, and strategic partnerships CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that its wholly owned subsidiary, Cana Laboratories S.A. (“Cana”), has advanced international patent application WO2025108566A1 into the European regional phase and the national phases in the United States, Australia, and Canada.
GlobeNewsWire6/25/2026Neutral
